Eslicarbazepine acetate + Eslicarbazepine acetate

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Epilepsy With Simple or Complex Partial Onset Seizures

Conditions

Epilepsy With Simple or Complex Partial Onset Seizures

Trial Timeline

Apr 1, 2009 โ†’ May 1, 2013

About Eslicarbazepine acetate + Eslicarbazepine acetate

Eslicarbazepine acetate + Eslicarbazepine acetate is a phase 3 stage product being developed by Sumitomo Pharma for Epilepsy With Simple or Complex Partial Onset Seizures. The current trial status is completed. This product is registered under clinical trial identifier NCT00866775. Target conditions include Epilepsy With Simple or Complex Partial Onset Seizures.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT03116828ApprovedCompleted
NCT00866775Phase 3Completed

Competing Products

20 competing products in Epilepsy With Simple or Complex Partial Onset Seizures

See all competitors
ProductCompanyStageHype Score
perampanelEisaiPhase 2
52
LacosamideUCBPhase 3
74
Zonisamide + PlaceboEisaiPhase 3
77
ZonegranEisaiApproved
85
perampanel + perampanelEisaiPhase 1
33
Perampanel + PlaceboEisaiApproved
85
perampanelEisaiApproved
85
E2007 + PlaceboEisaiPhase 2
52
Placebo + RufinamideEisaiPhase 3
77
E2007 (perampanel) + PlaceboEisaiPhase 2
52
Perampanel Oral TabletEisaiApproved
85
perampanelEisaiPhase 3
77
PerampanelEisaiPre-clinical
23
Zonisamide + CarbamazepineEisaiPhase 3
77
PerampanelEisaiApproved
85
Perampanel and Microgynon-30 + Perampanel and Microgynon-30EisaiPhase 1
33
PerampanelEisaiPhase 2
52
Zonisamide + PlaceboEisaiPhase 3
77
zonisamide low dose group + zonisamide high dose groupEisaiApproved
85
E2007 + E2007 + PlaceboEisaiPhase 2
52